Healthcare, Pharma & Life Sciences

Clinical Trial Services Market to Hit $97.4B by 2031, 8% CAGR

Image
Clinical Trial Services Market to Hit $97.4B by 2031, 8% CAGR

Delray Beach, Fla. – September 09, 2026 -- The global clinical trial services market will grow from $66.20 billion in 2026 to $97.41 billion by 2031, expanding at a compound annual growth rate of 8.0%, according to MarketsandMarkets.

North America commands 45% of the market as CRO density drives outsourcing demand

North America held the largest regional share in 2025, roughly 45%, anchored by a dense concentration of contract research organizations and established pharmaceutical R&D spending. Phase III trials accounted for the largest service share in 2025 at approximately 39.5%, reflecting the higher volume of outsourced work their complexity demands. Small molecules led by modality with a 50.5% share in 2025, supported by a large installed pipeline of drug candidates.

AtomVie Opens $160M Radiopharma Facility, Largest CDMO Site in North America

Image
AtomVie Opens $160M Radiopharma Facility, Largest CDMO Site in North America

Hamilton, ON – September 09, 2026 -- AtomVie Global Radiopharma has opened a 72,300-square-foot manufacturing facility at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest single-site CDMO facility in North America for radiopharmaceutical development.

New site delivers more than tenfold increase in manufacturing capacity

The purpose-built facility supports low-to-high throughput production, enabling AtomVie to scale operations from early clinical development through commercial manufacturing for its partners. The company is targeting a workforce of more than 200 employees by the end of 2026 as the site ramps toward full operational capacity.

Mabwell's 9MW1911 Cuts Severe COPD Exacerbations by 100% at High Dose

Shanghai – September 09, 2026 -- Mabwell (688062.SH, 02493.HK) reported that its anti-ST2 monoclonal antibody 9MW1911 reduced the annualized rate of severe COPD exacerbations by 100% in the 900 mg dose group compared with placebo, according to Phase Ib/IIa data presented as a poster at the European Respiratory Society International Congress 2026 (ERS 2026).

Trial enrolled 80 COPD patients across four dose arms

The randomized, double-blind, placebo-controlled study (9MW1911-C03) enrolled 80 former smokers with moderate-to-severe COPD, randomizing participants to intravenous 9MW1911 at 100 mg, 300 mg, 600 mg, or 900 mg, or placebo, every four weeks. Most participants had blood eosinophil counts of 300 cells/μL or below.

Pink Aid Launches 'Visionary Circle' to Scale Breast Cancer Financial Aid

Image
Pink Aid Launches 'Visionary Circle' to Scale Breast Cancer Financial Aid

Westport, Conn. – September 09, 2026 -- Pink Aid, the sole national nonprofit providing emergency financial aid to breast cancer patients, has launched the 'Visionary Circle,' a corporate advisory group aimed at expanding its national reach and fundraising capacity.

Breast cancer treatment drains $3.14 billion annually from U.S. patients

Out-of-pocket costs for breast cancer care can exceed $100,000 per year for some families, according to Pink Aid. Roughly one in three patients faces severe financial hardship during treatment, a figure that climbs to 78% among patients in low- and middle-income communities.

Pink Aid has distributed $6 million to 9,200 patients since 2015

The organization partners with more than 1,200 hospital social workers across 400 hospitals nationwide, delivering emergency funds within 48 hours to cover rent, utilities, groceries, and transportation costs during active treatment.

Baden-Württemberg Launches Action Plan for Self-Medication Policy

Image
Baden-Württemberg Launches Action Plan for Self-Medication Policy

Stuttgart – September 09, 2026 -- Pharma Deutschland's Baden-Württemberg chapter and MEDIVERBUND AG kicked off development of a regional action plan aimed at strengthening self-medication as a lever to relieve pressure on doctors' offices and build a more resilient healthcare system.

Industry and physician groups agree self-medication can free up doctor capacity

At the "Selbstverständlich Selbstmedikation" event, representatives from politics, medicine, pharmacies, health insurers and the pharmaceutical industry discussed conditions needed to expand patient self-treatment for minor ailments. Dr. Traugott Ullrich, chairman of Pharma Deutschland's Baden-Württemberg association, argued that low-threshold self-medication allows patients to treat or prevent minor health issues while pharmacies handle counseling and physicians retain capacity for more complex cases.

Tyra to Reveal SURF302 Bladder Cancer Data Sept. 9

Image
Tyra to Reveal SURF302 Bladder Cancer Data Sept. 9

Carlsbad – September 09, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will disclose initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) during a conference call scheduled for September 09, 2026, at 8:00 am ET.

Tyra sets September 9 call to unveil first SURF302 data

The clinical-stage biotech confirmed the call and webcast will present initial efficacy and safety data from the ongoing SURF302 trial, marking the first public disclosure of results for dabogratinib in this bladder cancer indication.

Dabogratinib targets FGFR3-driven tumors as lead pipeline asset

Dabogratinib is Tyra's lead precision medicine candidate, developed as a potential first-in-class selective FGFR3 inhibitor. Beyond IR NMIBC, the company is advancing the drug for low-grade upper tract urothelial cancer (LG-UTUC) and achondroplasia (ACH).

TFP Sells Illume Fertility to IVI RMA, Sharpens Canada Focus

Image
TFP Sells Illume Fertility to IVI RMA, Sharpens Canada Focus

Toronto – September 09, 2026 -- The Fertility Partners (TFP), Canada's largest fertility clinic network, has completed the sale of Illume Fertility, a Connecticut- and New York-based fertility practice, to IVI RMA North America, closing the deal on September 09, 2026.

TFP divests U.S. asset to concentrate capital on Canadian expansion

The transaction removes Illume from TFP's portfolio and redirects the company's capital, resources, and leadership attention toward growth opportunities across Canada. TFP CEO Heather Stark said the move reflects a deliberate portfolio decision, stating the company's strongest opportunities are in Canada and that the sale allows TFP to focus fully on building the country's leading fertility network.

Juvonno Opens API to 23+ Developers, Boosts Clinic Tech Stacks

Image
Juvonno Opens API to 23+ Developers, Boosts Clinic Tech Stacks

Winnipeg, MB – September 09, 2026 -- Juvonno has expanded its free Open API ecosystem to more than 23 software developers, giving clinics across Canada, the UK, and the USA access to AI-powered reception, reporting, and charting tools without added licensing costs.

Juvonno's free Open API now supports 23-plus third-party developers

The clinic management software provider is building connected solutions ranging from AI-driven reception systems to automated reporting and charting tools, all integrated with its core practice management platform. The API remains free for all Juvonno customers, removing a common cost barrier to third-party integration in the allied health software sector.

Orbis Flying Eye Hospital Debuts Simulation Training in Macau

Image
Orbis Flying Eye Hospital Debuts Simulation Training in Macau

Macau – September 09, 2026 -- Global eye care nonprofit Orbis International has launched its first-ever simulation-based training project in Macau, marking 20 years of local partnership that has raised more than US$33 million for the organization's work in China and worldwide.

Orbis brings 70 clinicians from eight Chinese hospitals for Flying Eye Hospital training

The project engages 70 ophthalmologists and nurses from eight Orbis partner hospitals across China, who will receive advanced training and mentorship aboard the Flying Eye Hospital aircraft and at Kiang Wu Nursing College of Macau. Training covers simulated cataract, glaucoma, strabismus, medical retina, and nursing specialties. Orbis states these professionals collectively serve more than 245,000 patients annually in China.

Dimerix Secures A$34M Non-Dilutive Loan to Fund Kidney Disease Trials

Melbourne – September 09, 2026 -- Dimerix Limited (ASX: DXB) has secured non-dilutive loan facility agreements worth up to A$34 million with a syndicate of Australian and U.S. lenders, expanding on its previously announced A$10 million SKIPTAN facility.

Dimerix locks in A$34 million loan facility from Australian, U.S. lenders

The new terms are substantially consistent with the earlier SKIPTAN agreement, with minor amendments made to standardise conditions across all lenders. The structure gives Dimerix the option to expand total commitments to A$50 million on or before September 09, 2026, though the company currently has no plans to draw on that additional capacity.